摘要
【摘要】目的：分析双黄连注射剂对急性上呼吸道感染（ AURI）的疗效情况。方法： 2017年 1月 -2018年 9月选取我院 86例 AURI患者，按照患者治疗方法不同，将其分为对照组（应用利巴韦林） 43例及观察组（应用双黄连注射剂） 43例，比较两组临床疗效及副反应发生率。结果：观察组临床总有效率为 95.35%，明显高于对照组 81.40%（ P<0.05）。两组副反应发生率对比， P>0.05，差异无统计学意义。结论：采用双黄连注射剂治疗 AURI具有安全性佳、疗效好等优点。 【关键词】双黄连注射剂； AURI；疗效；分析 [Abstract] Objective: to analyze the therapeutic effect of Shuanghuanglian Injection on acute upper respiratory tract infection (AURI). Methods: from January 2017 to September 2018, 86 cases of AURI in our hospital were selected. According to different treatment methods, they were divided into control group (ribavirin) 43 cases and observation group (Shuanghuanglian injection) 43 cases. The clinical efficacy and incidence of side effects of the two groups were compared. Results: the total clinical effective rate of the observation group was 95.35%, which was significantly higher than that of the control group (81.40%) (P < 0.05). There was no significant difference between the two groups (P > 0.05). Conclusion: Shuanghuanglian injection is safe and effective in the treatment of AURI.
出版日期
2019年12月17日（中国Betway体育网页登陆平台首次上网日期，不代表论文的发表时间）
